Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand

Applied Health Economics and Health Policy ◽

10.1007/s40258-016-0228-3 ◽

2016 ◽

Vol 14 (3) ◽

pp. 281-292 ◽

Author(s):

Unchalee Permsuwan ◽

Nathorn Chaiyakunapruk ◽

Piyameth Dilokthornsakul ◽

Kednapa Thavorn ◽

Surasak Saokaew

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Neutral Protamine Hagedorn

Download Full-text

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter]

Diabetologia ◽

10.1007/s00125-009-1492-7 ◽

2009 ◽

Vol 52 (10) ◽

pp. 2236-2239

Author(s):

J. Rosenstock ◽

V. Fonseca ◽

J. B. McGill ◽

M. Riddle ◽

J.-P. Hallé ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diabetic Retinopathy ◽

Insulin Glargine ◽

Nph Insulin ◽

Open Label Study ◽

Label Study ◽

Neutral Protamine Hagedorn

Download Full-text

An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes

Journal of Medical Economics ◽

10.3111/13696998.2014.991791 ◽

2015 ◽

Vol 18 (4) ◽

pp. 263-272 ◽

Author(s):

Vishal Gupta ◽

Ranya Baabbad ◽

Eva Hammerby ◽

Annie Nikolajsen ◽

Asrul Akmal Shafie

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Human Insulin ◽

Insulin Aspart ◽

Biphasic Insulin ◽

Biphasic Insulin Aspart 30 ◽

Neutral Protamine Hagedorn ◽

Download Full-text

Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cpp45203 ◽

2007 ◽

Vol 45 (04) ◽

pp. 203-221 ◽

Author(s):

M. Brändle ◽

M. Azoulay ◽

R.-A. Greiner

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Cost Utility ◽

Download Full-text

The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2008.00845.x ◽

2008 ◽

Vol 10 (s2) ◽

pp. 66-75 ◽

Author(s):

P. Levin

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Health Economics ◽

Insulin Glargine ◽

Neutral Protamine Hagedorn ◽

Download Full-text

PDB7 LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS INSULIN GLARGINE IN INSULIN NAÏVE PATIENTS WITH TYPE-2 DIABETES POORLY CONTROLLED ON ORAL HYPOGLYCEMIC AGENTS IN DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH, SWEDISH AND UK SETTINGS

Value in Health ◽

10.1016/s1098-3015(10)65950-5 ◽

2004 ◽

Vol 7 (6) ◽

pp. 736-737 ◽

Author(s):

M Lammert ◽

AJ Palmer ◽

S Roze ◽

ME Minshall ◽

WJ Valentine ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Insulin Aspart ◽

Hypoglycemic Agents ◽

Oral Hypoglycemic Agents ◽

Biphasic Insulin ◽

Biphasic Insulin Aspart 30

Download Full-text

Short and Long-Term Cost-Effectiveness of Switching Therapy from Insulin Glargine to Insulin Detemir in People with Type 2 Diabetes

Value in Health ◽

10.1016/j.jval.2013.08.2061 ◽

2013 ◽

Vol 16 (7) ◽

pp. A690

Author(s):

R. Malek ◽

G.G. Gálvez ◽

E. Hammerby ◽

A. Nikolajsen ◽

O. Henriksen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Insulin Detemir ◽

Switching Therapy ◽

Short And Long Term

Download Full-text

Letter to the Editor: Comments on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 vs insulin glargine in insulin naïve type 2 diabetes patients: cost effectiveness analysis in a UK setting

Current Medical Research and Opinion ◽

10.1185/030079906x104759 ◽

2006 ◽

Author(s):

Craig J. Currie ◽

Phil McEwan ◽

Chris Poole ◽

William J. Valentine ◽

Andrew J. Palmer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Insulin Aspart ◽

Biphasic Insulin ◽

Effectiveness Analysis ◽

Biphasic Insulin Aspart 30 ◽

Download Full-text

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study

Diabetologia ◽

10.1007/s00125-009-1415-7 ◽

2009 ◽

Vol 52 (9) ◽

pp. 1778-1788 ◽

Author(s):

J. Rosenstock ◽

V. Fonseca ◽

J. B. McGill ◽

M. Riddle ◽

J.-P. Hallé ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diabetic Retinopathy ◽

Insulin Glargine ◽

Nph Insulin ◽

Open Label Study ◽

Label Study ◽

Neutral Protamine Hagedorn

Download Full-text

PDB51 COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE AND VERSUS BIPHASIC INSULIN ASPART FOR THE TREATMENT OF TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM HEALTH ECONOMIC ANALYSIS

Value in Health ◽

10.1016/s1098-3015(11)72109-x ◽

2010 ◽

Vol 13 (7) ◽

pp. A293 ◽

Author(s):

JL Palmer ◽

CG Pinto ◽

R Duarte ◽

L Miguel ◽

Z Gregor

Keyword(s):

Type 2 Diabetes ◽

Health Economic ◽

Cost Effectiveness ◽

Economic Analysis ◽

Insulin Glargine ◽

Insulin Aspart ◽

Health Economic Analysis ◽

Biphasic Insulin

Download Full-text

Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-019-0180-9 ◽

2019 ◽

Vol 17 (1) ◽

Author(s):

E. Lau ◽

A. Salem ◽

J. C. N. Chan ◽

W. Y. So ◽

A. Kong ◽

...

Keyword(s):

Type 2 Diabetes ◽

Hong Kong ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Cost Effectiveness Analysis ◽

Nph Insulin ◽

Effectiveness Analysis ◽

Neutral Protamine Hagedorn

Download Full-text